Pancreaticoduodenectomy for duodenal papilla carcinoma: A single-centre 9-year retrospective study of 112 patients with long-term follow-up

Table 1 The serum levels of CA19-9 and CEA and clinical characteristics for 112 patients with duodenal papilla carcinoma

Characteristic	No.	Serum CA19-9		P value	Serum CEA		P value
		Negative	Positive		Negative	Positive
Gender				0.350			0.807
Male	74	46	28		63	11
Female	38	27	11		33	5
Age (yr)				0.621			0.699
< 60	61	41	20		53	8
> 60	51	32	19		43	8
Duration (yr)				0.938			0.699
< 1	54	35	19		47	7
> 1	58	38	20		49	9
Serum CA19-9 (U/mL)							0.000
< 120	73				69	4
> 120	39				27	12
Serum CEA (ng/mL)				0.000
< 5	96	69	27
> 5	16	4	12
Serum total bilirubin (μmol/L)				0.105			0.526
< 34.2	43	32	11		38	5
> 34.2	69	41	28		58	11
Bile pre-drainage				0.945			0.933
No	78	51	27		67	11
Yes	34	22	12		29	5
Tumour diameter (cm)				0.820			0.934
< 2	76	49	27		65	11
> 2	36	24	12		31	5
Pancreatic duct diameter (mm)				0.351			0.015
< 4	78	53	25		71	7
> 4	34	20	14		25	9
Drainage mode				0.033			0.928
Inside	85	60	25		73	12
Outside	27	13	14		23	4
End-to-end invagination				0.184			0.145
No	90	56	34		75	15
Yes	22	17	5		21	1
Blood loss (mL)				0.786			0.059
< 400	67	43	24		54	13
> 400	45	30	15		42	3
Delayed emptying				0.227			0.350
No	107	71	36		91	16
Yes	5	2	3		5	0
Pancreatic fistula				0.874			0.166
No	91	59	32		76	15
Yes	21	14	7		20	1
Differentiation				0.253			0.033
Well	40	24	16		37	3
Moderate	38	23	15		28	10
Poor	34	26	8		31	3
T stage				0.946			0.062
T1	14	10	4		14	0
T2	34	22	12		31	3
T3	35	23	12		30	5
T4	29	18	11		21	8
N stage				0.078			0.301
N0	88	61	27		77	11
N1	24	12	12		19	5
TNM stage				0.682			0.109
IA	14	10	4		14	0
IB	27	18	9		25	2
IIA	28	20	8		24	4
IIB	14	7	7		12	2
III

Table 2 Univariate analysis comparing overall survival to prognostic factors in 112 patients with duodenal papilla carcinoma

Factors	No.	5 years survival	χ²	P value
Gender			0.561	0.454
Male	74	48.6%
Female	38	52.4%
Age (yr)			0.022	0.883
< 60	61	46.3%
> 60	51	48.9%
Duration (yr)			0.409	0.523
< 1	54	41.7%
> 1	58	53.4%
Serum CA19-9 (U/mL)			4.566	0.033
< 120	73	56.2%
> 120	39	38.3%
Serum CEA (ng/mL)			5.554	0.018
< 5	96	54.1%
> 5	16	25.0%
Serum total bilirubin (μmol/L)			5.929	0.015
< 34.2	43	65.1%
> 34.2	69	40.6%
Bile pre-drainage			1.144	0.285
No	78	47.4%
Yes	34	55.9%
Tumour diameter (cm)			0.185	0.667
< 2	76	51.3%
> 2	36	47.2%
Pancreatic duct diameter (mm)			0.493	0.483
< 4	78	51.2%
> 4	34	47.1%
Drainage mode			0.006	0.939
Inside	85	48.2%
Outside	27	55.3%
End-to-end invagination			0.592	0.442
No	90	48.9%
Yes	22	54.5%
Blood loss (mL)			0.052	0.820
< 400	67	49.2%
> 400	45	51.1%
Delayed emptying			0.614	0.433
No	107	50.5%
Yes	5	40.0%
Pancreatic fistula			0.455	0.500
No	91	47.1%
Yes	21	57.1%
Differentiation			3.676	0.159
Well	40	62.4%
Moderate	38	39.5%
Poor	34	47.1%
Infiltration depth			22.424	0.000
T1	14	78.6%
T2	34	67.6%
T3	35	45.7%
T4	29	20.7%
lymph metastases			21.187	0.000
N0	88	60.2%
N1	24	12.5%
TNM stage			35.041	0.000
IA	14	78.6%
IB	27	77.8%
IIA	28	57.1%
IIB	14	14.3%
III	29	20.7%

Table 3 Multivariate analysis comparing overall survival to prognostic factors in 112 patients with duodenal papilla carcinoma

Factors	No.	5 years survival	Median survival (95%CI)(mo)	Relative risk (95%CI)	P value
CA19-9 (U/mL)					0.174
< 120	73	56.2%	141.0 (3.3-278.6)	1
> 120	39	38.3%	45.0 (22.6-67.4)	1.550 (0.823-2.920)
CEA (ng/mL)					0.528
< 5	96	54.1%	80.0 (10.4-149.5)	1
> 5	16	25.0%	30.0 (18.2-41.8)	1.270 (0.605-2.663)
Bilirubin (μmol/L)					0.264
< 34.2	43	65.1%		1
> 34.2	69	40.6%	45.0 (29.9-60.1)	1.408 (0.772-2.566)
Differentiation					0.137
Well	40	62.4%	141.0	1
Moderate	38	39.5%	44.0 (3.09-57.1)	0.808 (0.399-1.635)	0.553
Poor	34	47.1%	52.0 (3.552-100.4)	1.636 (0.814-3.285)	0.167
Infiltration depth					0.022
T1 + T2	48	70.8%		1
T3 + T4	64	34.4%	39.0 (26.3-51.7)	2.211 (1.119-4.367)
lymph metastases					0.142
N0	88	60.2%	141.0	1
N1	24	12.5%	28.0 (6.1-113.9)	1.744 (0.830-3.666)
TNM stage					0.047
IA + IB + IIA	69	69.5%		1
IIB + III	43	18.6%	28.0 (21.6-34.4)	2.109 (1.010-4.406)